...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Canadian journal of hospital pharmacy. >Response from Matthew Tsang, Aaron Tejani,and 1 fan Kuo
【24h】

Response from Matthew Tsang, Aaron Tejani,and 1 fan Kuo

机译：Matthew Tsang，Aaron Tejani和1 fan Kuo的回应

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We thank Drs. Eikelboom and Connolly for responding to our previous letter and for providing their interpretation of the data from the RE-LY trial. Although their letter provides useful insights, it does not directly answer our questions and concerns about the trial. We also disagree with their conclusion that "the RE-LY trial data conclusively demonstrated a net clinical benefit of both doses of dabigatran relative to warfarin." As such, we remain convinced that it is inappropriate to imply that dabigatran offers a clear advantage over warfarin for patients with atrial fibrillation, solely on the basis of the published results of the RE-LY trial. We will attempt to explain our concerns in more detail here.
机译：我们感谢博士。 Eikelboom和Connolly回复了我们的上一封信，并解释了RE-LY试验的数据。尽管他们的来信提供了有用的见解，但并未直接回答我们对审判的疑问和疑虑。我们也不同意他们的结论，即“ RE-LY试验数据最终证明了两种剂量的达比加群相对于华法林的净临床获益。”因此，我们仍然坚信仅根据RE-LY试验的已发表结果，暗示达比加群对房颤患者具有比华法林明显的优势是不合适的。我们将在这里尝试更详细地解释我们的担忧。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号